Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7020087 | 0.78 | NOS2 (0.70) | NOS2LMNACYP2C19ALDH1A1 | |
| SCHEMBL8082501 | 0.77 | NOS2 (0.47) | NOS2LMNAHTTGRIN2DGRIN3B | |
| SCHEMBL6682638 | 0.75 | NOS2 (0.46) | NOS2LMNAHTTGRIN2DGRIN3B | |
| SCHEMBL22180009 | 0.75 | NOS2 (0.46) | NOS2HTTGRIN2DGRIN3BGRIN1 | |
| Hydrochloric Acid SCHEMBL8079624 | 0.75 | NOS2 (0.46) | NOS2LMNAHTTGRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL7327781 | 0.69 | CA12 (0.47) | NOS2HTTCYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL10822383 | 0.68 | EPHX1 (0.53) | LMNA | |
| SCHEMBL9697406 | 0.67 | — | — | |
| SCHEMBL1382152 | 0.67 | — | — | |
| SCHEMBL426212 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0914333-B1 | PEPTIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| EP-0932618-B1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | ASTRAZENECA AB (SE) | 2003-12-10 | — | — | EP | disclosed |
| US-20030195158-A1 | Peptide derivatives | SYNGENTA LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| EP-0946589-B1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| US-6541453-B2 | Amino acid sequences for use in the treatment of autoimmune or inflammatory diseases | SYNGENTA LIMITED (GB) | 2003-04-01 | — | — | US | disclosed |
| US-20020187934-A1 | Peptide derivatives | SYNGENTA LIMITED (GB) | 2002-12-12 | — | — | US | disclosed |
| US-20020103335-A1 | PEPTIDE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2002-08-01 | — | — | US | disclosed |
| US-6355617-B1 | PEPTIDES, HYDROPHOBIC RESIDUES, AMINO ACIDS AND SEQUENCE | SYNGENTA LIMITED (GB) | 2002-03-12 | — | — | US | disclosed |
| US-6207644-B1 | FOR USE IN TREATING MHC CLASS II DEPENDENT T-CELL MEDIATED AUTOIMMUNE OR INFLAMMATORY DISEASES, SUCH AS RHEUMATOID ARTHRITIS | ZENECA LIMITED (GB) | 2001-03-27 | — | — | US | disclosed |
| US-6184207-B1 | A PEPTIDE INCLUDING SPECIFIED PIPERIDINE-CONTAINING GROUP, HAVING AN N-TERMINAL HYDROPHOBIC RESIDUE AND OPTIONALLY AN AMIDATED C-TERMINAL OF SPECIFIED END GROUPS; TREATING MULTIPLE SCLEROSIS OR RHEUMATOID ARTHRITIS | ZENECA LIMITED (GB) | 2001-02-06 | — | — | US | disclosed |
| EP-0882066-B1 | PEPTIDE DERIVATIVES | ZENECA LTD (GB) | 2000-09-06 | — | — | EP | disclosed |
| US-6087336-A | ANTIINFLAMMATORY AGENT TREATING RHEUMATOID ARTHRITIS | ZENECA LIMITED (GB) | 2000-07-11 | — | — | US | disclosed |
| EP-0946589-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| EP-0932618-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | AstraZeneca AB (SE) | 1999-08-04 | — | — | EP | disclosed |
| EP-0914333-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1999-05-12 | — | — | EP | disclosed |
| EP-0882066-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998025951-A1 | INHIBITORS OF PEPTIDE BINDING TO MHC CLASS II PROTEINS | ZENECA LIMITED (GB) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998017680-A1 | PEPTIDE ANALOGUES CONTAINING A 7-MEMBERED LACTAM RING | ZENECA LIMITED (GB) | 1998-04-30 | — | — | WO | disclosed |
| WO-1997046578-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997031023-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195158-A1 | Peptide derivatives | HLA-DRB1, MICA, CD74 | NOS2 697/4885LMNA 4844/4885HTT 1036/4885 |
| US-20020103335-A1 | PEPTIDE DERIVATIVES | HLA-DRB1, MICA, TAP1 | NOS2 1377/4885LMNA 4479/4885HTT 2971/4885 |
| US-20020187934-A1 | Peptide derivatives | HLA-DRB1, MICA, TAP1 | NOS2 1304/4885LMNA 4839/4885HTT 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.